Mary Bates, PhD

A Major Milestone in Cystic Fibrosis Treatment

A triple medication combination could be life-changing for the majority of patients with cystic fibrosis.

November 25, 2019 | Written by Mary Bates, PhD

Cystic Fibrosis, Pulmonary Medicine

Health Care Leaders Offer Interim Guidelines on Vaping and EVALI Care

While investigations are ongoing, an interim report offers clinical guidance regarding vaping-associated lung injuries.

November 17, 2019 | Written by Mary Bates, PhD

Emergency Medicine, General Pediatrics, Pulmonary Medicine

Gene Expression Changes With CFTR Modulator Treatment

Patients with cystic fibrosis show transcriptomic changes after starting treatment with lumacaftor/ivacaftor.

September 30, 2019 | Written by Mary Bates, PhD

Center for Microbial Pathogenesis, Cystic Fibrosis, Pulmonary Medicine

Long-Term Follow Up of Patients Receiving Novel Gene Therapy for SMA Type I

April 19, 2019 | Written by Abbie Roth

Center for Gene Therapy, Pulmonary Medicine

Toward a Cell-based Therapy for Cystic Fibrosis Lung Disease

April 19, 2019 | Written by Jeb Phillips

Center for Perinatal Research, Pulmonary Medicine

Do All Cystic Fibrosis Modulators Improve Killing of Bacteria?

Treated immune cells function properly to kill more bacteria, depending on the treatment and the bacteria.

February 12, 2019 | Written by Lauren Dembeck

Cystic Fibrosis, Pulmonary Medicine

New Guidelines for Home Oxygen Therapy in Pediatric Patients

February 1, 2019 | Written by Abbie Roth

Pulmonary Medicine

Researchers Identify Proteins Triggering Imbalance of Cells in Chronic Lung Disease

A protein that triggers an imbalance of mucous and ciliated cells in patients with chronic lung disease could be a target for treatments to restore airways.

November 20, 2018 | Written by Kevin Mayhood

Center for Perinatal Research, Neonatology, Pulmonary Medicine, Research

1
2